X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The net proceeds will be used in the development of CK-301 (cosibelimab), which is an anti-programmed death-ligand for the treatment of patients with selected recurrent or metastatic cancers, including metastatic and locally advanced cutaneous squamous cell carcinoma.
Lead Product(s): Cosibelimab
Therapeutic Area: Oncology Product Name: CK-301
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $14.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 29, 2024
Details:
CK-301 (cosibelimab) is a fully-human mAb of IgG1 subtype that directly binds to PD-L1 and blocks the PDL1 interaction with the PD-1 and B7.1 receptors. It is under phase 3 clinical development for the treatment of cutaneous squamous cell carcinoma.
Lead Product(s): Cosibelimab
Therapeutic Area: Oncology Product Name: CK-301
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 18, 2023
Details:
Checkpoint intends to use the proceeds for the manufacturing of CK-301 (cosibelimab), a potential best-in-class anti-PD-L1 antibody being developed in patients with selected recurrent or metastatic cancers.
Lead Product(s): Cosibelimab
Therapeutic Area: Oncology Product Name: CK-301
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $11.1 million Upfront Cash: Undisclosed
Deal Type: Public Offering October 02, 2023
Details:
Checkpoint intends to use the net proceeds for the manufacturing of CK-301 (cosibelimab), a potential best-in-class anti-PD-L1 antibody, being developed for advanced cutaneous squamous cell carcinoma.
Lead Product(s): Cosibelimab,Cisplatin,Pemetrexed
Therapeutic Area: Oncology Product Name: CK-301
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $10.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering July 31, 2023
Details:
CK-301 (cosibelimab) is a fully-human mAb of IgG1 subtype that directly binds to PD-L1 and blocks the PDL1 interaction with the PD-1 and B7.1 receptors, which removes the suppressive effects of PD-L1 on anti-tumor CD8+ T-cells to restore the cytotoxic T cell response.
Lead Product(s): Cosibelimab
Therapeutic Area: Oncology Product Name: CK-301
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 27, 2023
Details:
Checkpoint intends to use the net proceeds for the manufacturing of CK-301 (cosibelimab), a fully human monoclonal antibody of IgG1 subtype that directly binds to PD-L1 and certain pre-commercial activities in anticipation of potential approval and commercial launch.
Lead Product(s): Cosibelimab,Pemetrexed,Cisplatin
Therapeutic Area: Oncology Product Name: CK-301
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $10.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 23, 2023
Details:
Checkpoint intends to use the net proceeds of this offering for the manufacturing of CK-301 (cosibelimab) and certain pre-commercial activities in anticipation of potential approval and commercial launch.
Lead Product(s): Cosibelimab,Pemetrexed,Cisplatin
Therapeutic Area: Oncology Product Name: CK-301
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $6.1 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 31, 2023
Details:
CK-301 (cosibelimab) is a fully-human mAb of IgG1 subtype that directly binds to PD-L1 and blocks the PDL1 interaction with the PD-1 and B7.1 receptors, which removes the suppressive effects of PD-L1 on anti-tumor CD8+ T-cells to restore the cytotoxic T cell response.
Lead Product(s): Cosibelimab,Pemetrexed,Cisplatin
Therapeutic Area: Oncology Product Name: CK-301
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 02, 2023
Details:
Checkpoint intends to use the net proceeds for the manufacturing of CK-301 (cosibelimab), a potential best-in-class anti-PD-L1 antibody, and certain pre-commercial activities in anticipation of potential approval and commercial launch.
Lead Product(s): Cosibelimab,Pemetrexed,Cisplatin
Therapeutic Area: Oncology Product Name: CK-301
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $7.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 21, 2023
Details:
CK-301 (cosibelimab) is a fully human monoclonal antibody of IgG1 subtype that directly binds to Programmed Death-Ligand 1 (PD-L1) and blocks its interactions with the Programmed Death-1 (PD-1) and B7.1 receptors.
Lead Product(s): Cosibelimab,Pemetrexed,Cisplatin
Therapeutic Area: Oncology Product Name: CK-301
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $7.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering December 15, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
